ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the...To view the full article, register now.
Already a subscriber? Click here to view full article